Reltecimod |
P2-TA; AB-103 |
Phase 3 Clinical |
Atox Bio Ltd |
Peritonitis; Acute Kidney Injury; Fasciitis, Necrotizing; Fournier Gangrene; Soft Tissue Infections |
Details
|
Nezastomig |
REGN-5678 |
Phase 2 Clinical |
|
Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
Abatacept (Orban Biotech) |
|
Phase 2 Clinical |
Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases |
Diabetes Mellitus, Type 1 |
Details
|
Lulizumab pegol |
Lulizumab; BMS-931699 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Lupus Vulgaris; Rejection of renal transplantation; Sjogren-Larsson Syndrome |
Details
|
Acazicolcept |
ALPN-101 |
Phase 2 Clinical |
Alpine Immune Sciences Inc |
Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation |
Details
|
FR-104 |
FR-104; JNJ-3133; VEL-101 |
Phase 2 Clinical |
Effimune |
Rejection of renal transplantation; Arthritis, Rheumatoid; Postoperative Complications |
Details
|
TC-510 |
TC-510 |
Phase 2 Clinical |
Tcr2 Therapeutics Inc |
Ovarian Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Mesothelioma; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
REGN-7075 |
REGN-7075 |
Phase 2 Clinical |
|
Solid tumours |
Details
|
REGN-5668 |
REGN-5668 |
Phase 2 Clinical |
|
Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms |
Details
|
ATLCAR.k.CD28 cells (UNC Lineberger Comprehensive Cancer Center) |
|
Phase 1 Clinical |
Unc Lineberger Comprehensive Cancer Center |
Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma |
Details
|
SAR-442257 |
SAR-442257 |
Phase 1 Clinical |
Sanofi |
Neoplasms |
Details
|
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) |
|
Phase 1 Clinical |
City Of Hope National Medical Center |
Lymphoma, Non-Hodgkin |
Details
|
JNJ-1493 |
JNJ-1493 |
Phase 1 Clinical |
Xencor Inc |
Hematologic Neoplasms; Lymphoma, B-Cell |
Details
|
JNJ-9401 |
JNJ-9401 |
Phase 1 Clinical |
Xencor Inc |
Prostatic Neoplasms |
Details
|
JNJ-87189401 |
JNJ-87189401 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Prostatic Neoplasms |
Details
|
REGN5837 |
REGN5837; REGN-5837 |
Phase 1 Clinical |
|
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
CC-312 |
CC-312 |
Phase 1 Clinical |
CytoCares (Shanghai) Inc |
Hematologic Neoplasms; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
RG-6333 |
RO-7443904 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ag |
Lymphoma, Non-Hodgkin |
Details
|
XmAb-808 |
XmAb808 |
Phase 1 Clinical |
Xencor Inc |
Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
SAR-443216 |
SAR-443216 |
Phase 1 Clinical |
Sanofi |
Solid tumours; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms |
Details
|
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) |
|
Phase 1 Clinical |
Second Affiliated Hospital Of Zhejiang University School Of Medicine |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Primary mediastinal B cell lymphoma |
Details
|
FPT-155 |
CD80-Fc; FPT-155 |
Phase 1 Clinical |
Five Prime Therapeutics Inc |
Solid tumours |
Details
|
Theralizumab |
TAB-08; TABO-8 |
Phase 1 Clinical |
Theramab Llc |
Solid tumours; Carcinoma, Merkel Cell; Arthritis, Rheumatoid; Psoriasis; Lupus Erythematosus, Systemic |
Details
|
B7-2/GM-CSF cancer gene therapy |
CIT |
Phase 1 Clinical |
Radient |
Neoplasms |
Details
|
InHeAb-01 |
InHeAb-01; bsAB |
Clinical |
University Hospital Tuebingen |
Neoplasms |
Details
|
Reltecimod |
P2-TA; AB-103 |
Phase 3 Clinical |
Atox Bio Ltd |
Peritonitis; Acute Kidney Injury; Fasciitis, Necrotizing; Fournier Gangrene; Soft Tissue Infections |
Details
|
Nezastomig |
REGN-5678 |
Phase 2 Clinical |
|
Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
Abatacept (Orban Biotech) |
|
Phase 2 Clinical |
Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases |
Diabetes Mellitus, Type 1 |
Details
|
Lulizumab pegol |
Lulizumab; BMS-931699 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Lupus Vulgaris; Rejection of renal transplantation; Sjogren-Larsson Syndrome |
Details
|
Acazicolcept |
ALPN-101 |
Phase 2 Clinical |
Alpine Immune Sciences Inc |
Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation |
Details
|
FR-104 |
FR-104; JNJ-3133; VEL-101 |
Phase 2 Clinical |
Effimune |
Rejection of renal transplantation; Arthritis, Rheumatoid; Postoperative Complications |
Details
|
TC-510 |
TC-510 |
Phase 2 Clinical |
Tcr2 Therapeutics Inc |
Ovarian Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Mesothelioma; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
REGN-7075 |
REGN-7075 |
Phase 2 Clinical |
|
Solid tumours |
Details
|
REGN-5668 |
REGN-5668 |
Phase 2 Clinical |
|
Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms |
Details
|
ATLCAR.k.CD28 cells (UNC Lineberger Comprehensive Cancer Center) |
|
Phase 1 Clinical |
Unc Lineberger Comprehensive Cancer Center |
Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma |
Details
|
SAR-442257 |
SAR-442257 |
Phase 1 Clinical |
Sanofi |
Neoplasms |
Details
|
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) |
|
Phase 1 Clinical |
City Of Hope National Medical Center |
Lymphoma, Non-Hodgkin |
Details
|
JNJ-1493 |
JNJ-1493 |
Phase 1 Clinical |
Xencor Inc |
Hematologic Neoplasms; Lymphoma, B-Cell |
Details
|
JNJ-9401 |
JNJ-9401 |
Phase 1 Clinical |
Xencor Inc |
Prostatic Neoplasms |
Details
|
JNJ-87189401 |
JNJ-87189401 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Prostatic Neoplasms |
Details
|
REGN5837 |
REGN5837; REGN-5837 |
Phase 1 Clinical |
|
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
CC-312 |
CC-312 |
Phase 1 Clinical |
CytoCares (Shanghai) Inc |
Hematologic Neoplasms; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
RG-6333 |
RO-7443904 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ag |
Lymphoma, Non-Hodgkin |
Details
|
XmAb-808 |
XmAb808 |
Phase 1 Clinical |
Xencor Inc |
Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
SAR-443216 |
SAR-443216 |
Phase 1 Clinical |
Sanofi |
Solid tumours; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms |
Details
|
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) |
|
Phase 1 Clinical |
Second Affiliated Hospital Of Zhejiang University School Of Medicine |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Primary mediastinal B cell lymphoma |
Details
|
FPT-155 |
CD80-Fc; FPT-155 |
Phase 1 Clinical |
Five Prime Therapeutics Inc |
Solid tumours |
Details
|
Theralizumab |
TAB-08; TABO-8 |
Phase 1 Clinical |
Theramab Llc |
Solid tumours; Carcinoma, Merkel Cell; Arthritis, Rheumatoid; Psoriasis; Lupus Erythematosus, Systemic |
Details
|
B7-2/GM-CSF cancer gene therapy |
CIT |
Phase 1 Clinical |
Radient |
Neoplasms |
Details
|
InHeAb-01 |
InHeAb-01; bsAB |
Clinical |
University Hospital Tuebingen |
Neoplasms |
Details
|